Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Yokohama Biotech Startup To Grow Biosimilar Business

This article was originally published in PharmAsia News

Yokohama BioResearch & Supply has started a contract biosimilar development and manufacturing business.

Targeting medium and small sized drug makers, the company projects more drug makers will enter the biosimilar space. With a sales goal of ¥600 million in five years, the company will conduct research for drug makers that do not have their own biopharmaceutical knowhow and capacity. Negotiation are ongoing with one firm, and YBRS plans to eventually expand to three companies by 2015. (Click here for more – Japanese language)

“Yokohama Bioresearch And Supply Enters Biosimilar Support Business” – Nikkei Sangyo News (11/10/2011)

Table

View full table

Tags:
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC076699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By